A therapeutic trial of radiation therapy with Vincristine, etoposide, and Procarbazine (VVP) in high grade intracranial gliomas - An Eastern Cooperative Oncology Group Study (E2392)

Richard Hellman, Donna S. Neuberg, Henry Wagner, Margaret Grunnet, H. Ian Robins, Daniel Karp, Patrick Flynn, George Adams

Research output: Contribution to journalArticlepeer-review

11 Scopus citations

Abstract

This study is a combined modality Phase II therapeutic trial to determine the efficacy of the novel combination of VP-16, Vincristine and Procarbazine in addition to postoperative radiation therapy in patients with high grade intracranial gliomas. Thirty three patients (median age 51 years) were entered (27 with glioblastoma multiforme, 6 with anaplastic astrocytoma). Toxicity was manageable with no lethal toxicities. Five of seven life threatening toxicities were hematologic. Median overall survival was 14.2 months. These data suggest this regimen is effective treatment for patients with high grade gliomas.

Original languageEnglish (US)
Pages (from-to)55-62
Number of pages8
JournalJournal of neuro-oncology
Volume37
Issue number1
DOIs
StatePublished - Feb 25 1998

All Science Journal Classification (ASJC) codes

  • Oncology
  • Neurology
  • Clinical Neurology
  • Cancer Research

Fingerprint Dive into the research topics of 'A therapeutic trial of radiation therapy with Vincristine, etoposide, and Procarbazine (VVP) in high grade intracranial gliomas - An Eastern Cooperative Oncology Group Study (E2392)'. Together they form a unique fingerprint.

Cite this